135 related articles for article (PubMed ID: 8301103)
41. Estimation of 'total' renal, cardiac and splanchnic sympathetic nervous tone in essential hypertension from measurements of noradrenaline release.
Esler MD; Jennings GL; Johns J; Burke F; Little PJ; Leonard P
J Hypertens Suppl; 1984 Dec; 2(3):S123-5. PubMed ID: 6599657
[TBL] [Abstract][Full Text] [Related]
42. Determination of noradrenaline uptake, spillover to plasma and plasma concentration in patients with essential hypertension.
Esler M; Jackman G; Leonard P; Bobik A; Skews H; Jennings G; Kelleher D; Korner P
Clin Sci (Lond); 1980 Dec; 59 Suppl 6():311s-313s. PubMed ID: 7449275
[TBL] [Abstract][Full Text] [Related]
43. Plasma norepinephrine and dihydroxyphenylglycol in essential hypertension.
Ludwig J; Gerlich M; Halbrügge T; Graefe KH
Hypertension; 1991 Apr; 17(4):546-52. PubMed ID: 2013481
[TBL] [Abstract][Full Text] [Related]
44. Noradrenaline spillover and microneurography measurements in patients with primary hypertension.
Jennings GL
J Hypertens Suppl; 1998 Aug; 16(3):S35-8. PubMed ID: 9747908
[TBL] [Abstract][Full Text] [Related]
45. Sympathetic activity and presynaptic adrenoceptor function in patients with longstanding essential hypertension.
Chang PC; Kriek E; van Brummelen P
J Hypertens; 1994 Feb; 12(2):179-90. PubMed ID: 8021470
[TBL] [Abstract][Full Text] [Related]
46. Noradrenaline release and the pathophysiology of primary human hypertension.
Esler M; Jennings G; Lambert G
Am J Hypertens; 1989 Mar; 2(3 Pt 2):140S-146S. PubMed ID: 2647104
[TBL] [Abstract][Full Text] [Related]
47. Evidence of increased peripheral catecholamine release in patients with long-standing, untreated essential hypertension.
Kjeldsen SE; Flaaten B; Eide I; Helgeland A; Leren P
Scand J Clin Lab Invest; 1982 May; 42(3):217-23. PubMed ID: 7134805
[TBL] [Abstract][Full Text] [Related]
48. Differential effects of sino-aortic denervations on cardiac noradrenaline stores, turnover and neuronal re-uptake in normotensive and renal hypertensive rabbits.
Snell J; Korner P; Bobik A
J Hypertens; 1986 Aug; 4(4):413-20. PubMed ID: 3772095
[TBL] [Abstract][Full Text] [Related]
49. Paring down on Descartes: a review of brain noradrenaline and sympathetic nervous function.
Lambert GW
Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):979-82. PubMed ID: 11903297
[TBL] [Abstract][Full Text] [Related]
50. Plasma noradrenaline in cirrhosis: a study of kinetics and temporal relationship to ascites formation.
Macgilchrist AJ; Howes LG; Hawksby C; Reid JL
Eur J Clin Invest; 1991 Apr; 21(2):238-43. PubMed ID: 1905638
[TBL] [Abstract][Full Text] [Related]
51. Biochemical evidence of sympathetic hyperactivity in human hypertension.
Esler M; Ferrier C; Lambert G; Eisenhofer G; Cox H; Jennings G
Hypertension; 1991 Apr; 17(4 Suppl):III29-35. PubMed ID: 2013490
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of elevated heart rate as a sympathetic nervous system biomarker in essential hypertension.
Esler M; Lambert G; Esler D; Ika Sari C; Guo L; Jennings G
J Hypertens; 2020 Aug; 38(8):1488-1495. PubMed ID: 32195820
[TBL] [Abstract][Full Text] [Related]
53. Study of noradrenaline uptake and spillover to plasma in normal subjects and patients with essential hypertension.
Esler M; Leonard P; Jackman G; Bobik A; Skews H
Prog Biochem Pharmacol; 1980; 17():75-83. PubMed ID: 7208506
[TBL] [Abstract][Full Text] [Related]
54. Total, and organ-specific, noradrenaline plasma kinetics in essential hypertension.
Esler M; Jennings G; Korner P; Blombery P; Burke F; Willett I; Leonard P
Clin Exp Hypertens A; 1984; 6(1-2):507-21. PubMed ID: 6697562
[TBL] [Abstract][Full Text] [Related]
55. The influence of aging on the human sympathetic nervous system and brain norepinephrine turnover.
Esler M; Hastings J; Lambert G; Kaye D; Jennings G; Seals DR
Am J Physiol Regul Integr Comp Physiol; 2002 Mar; 282(3):R909-16. PubMed ID: 11832414
[TBL] [Abstract][Full Text] [Related]
56. Clinical aspects on presynaptic noradrenaline metabolism.
Ludwig J; Halbrügge T; Graefe KH
J Neural Transm Suppl; 1991; 34():69-75. PubMed ID: 1817166
[TBL] [Abstract][Full Text] [Related]
57. The effects of dietary weight loss on indices of norepinephrine turnover: modulatory influence of hyperinsulinemia.
Straznicky NE; Lambert EA; Grima MT; Eikelis N; Richards K; Nestel PJ; Dawood T; Masuo K; Sari CI; Dixon JB; Esler MD; Paul E; Schlaich MP; Lambert GW
Obesity (Silver Spring); 2014 Mar; 22(3):652-62. PubMed ID: 23997009
[TBL] [Abstract][Full Text] [Related]
58. NPY and NPY Y1 receptor effects on noradrenaline overflow from the rat brain in vitro.
Hastings JA; Morris MJ; Lambert G; Lambert E; Esler M
Regul Pept; 2004 Aug; 120(1-3):107-12. PubMed ID: 15177927
[TBL] [Abstract][Full Text] [Related]
59. High blood pressure management: potential benefits of I1 agents.
Esler M
J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906
[TBL] [Abstract][Full Text] [Related]
60. Differential inhibition of noradrenaline release mediated by inhibitory A₁-adenosine receptors in the mesenteric vein and artery from normotensive and hypertensive rats.
Rocha-Pereira C; Sousa JB; Vieira-Rocha MS; Fresco P; Gonçalves J; Diniz C
Neurochem Int; 2013 Mar; 62(4):399-405. PubMed ID: 23416044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
